Education
About Us
Working with TipRanks
Follow Us
Vaxcyte, Inc. (PCVX)
NASDAQ:PCVX
PCVX Stock Chart & Stats
$56.15
-$2.14(-2.45%)
At close: 4:00 PM EST
$56.15
-$2.14(-2.45%)
Day’s Range― - ―
52-Week Range$27.66 - $87.42
Previous CloseN/A
Volume105.48K
Average Volume (3M)1.37M
Market Cap
$7.97B
Enterprise Value$7.77B
Total Cash (Recent Filing)$1.71B
Total Debt (Recent Filing)$84.44M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Mar 02, 2026EPS Estimate
-1.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.56
Shares Outstanding141,906,270
10 Day Avg. Volume2,097,825
30 Day Avg. Volume1,370,398
Financial Highlights & Ratios
PEG Ratio2.62
Price to Book (P/B)3.02
Price to Sales (P/S)0.00
P/FCF Ratio-21.02
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.56K
Enterprise Value/Ebitda-12.96
Forecast
1Y Price Target
$118.50Price Target Upside111.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressAnalyst notes the adult pivotal Phase 3 OPUS trial has begun dosing and enrollment is progressing, positioning the program for high-impact readouts that could prompt reassessment of the stock.
Financial Position And RunwayAnalyst highlights a strong balance sheet with about $2.7 billion in cash and investments, providing runway to 2028 to fund trials and sustain operations through upcoming catalysts.
Vaccine Efficacy And CoverageAnalyst highlights VAX-31's broad serotype coverage and higher-dose design, which could deliver materially greater protection than current standard vaccines and support leadership in adult and pediatric markets.
Bears Say
Pediatric Efficacy RiskAnalyst notes VAX-24 produced pediatric results that were materially weaker than adult data, creating uncertainty about performance and potential adoption in children.
Regulatory And Comparability RiskAnalyst projects VAX-31 may not meet non-inferiority versus PCV20 for multiple serotypes, a shortfall that could complicate regulatory review and limit pediatric market uptake.
Vaxcyte News
PCVX FAQ
What was Vaxcyte, Inc.’s price range in the past 12 months?
Vaxcyte, Inc. lowest stock price was $27.66 and its highest was $87.42 in the past 12 months.
What is Vaxcyte, Inc.’s market cap?
Vaxcyte, Inc.’s market cap is $7.97B.
When is Vaxcyte, Inc.’s upcoming earnings report date?
Vaxcyte, Inc.’s upcoming earnings report date is Mar 02, 2026 which is in 21 days.
How were Vaxcyte, Inc.’s earnings last quarter?
Vaxcyte, Inc. released its earnings results on Nov 04, 2025. The company reported -$1.56 earnings per share for the quarter, missing the consensus estimate of -$1.238 by -$0.322.
Is Vaxcyte, Inc. overvalued?
According to Wall Street analysts Vaxcyte, Inc.’s price is currently Undervalued.
Does Vaxcyte, Inc. pay dividends?
Vaxcyte, Inc. does not currently pay dividends.
What is Vaxcyte, Inc.’s EPS estimate?
Vaxcyte, Inc.’s EPS estimate is -1.53.
How many shares outstanding does Vaxcyte, Inc. have?
Vaxcyte, Inc. has 141,906,270 shares outstanding.
What happened to Vaxcyte, Inc.’s price movement after its last earnings report?
Vaxcyte, Inc. reported an EPS of -$1.56 in its last earnings report, missing expectations of -$1.238. Following the earnings report the stock price went down -2.491%.
Which hedge fund is a major shareholder of Vaxcyte, Inc.?
Currently, no hedge funds are holding shares in PCVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vaxcyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$118.50 (111.04% Upside)
$118.50 (111.04% Upside)
Blogger Sentiment
Bullish
PCVX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 260.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $321.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-36.92%
12-Months-Change
Fundamentals
Return on Equity
-20.83%
Trailing 12-Months
Asset Growth
-10.90%
Trailing 12-Months
Company Description
Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
PCVX Stock 12 Month Forecast
Average Price Target
$118.50
▲(111.04% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---